Personalized Cancer Medicine: Molecular Diagnostics, Predictive biomarkers, and Drug Resistance

Clinical Pharmacology and Therapeutics

Volumn 93, Issue 3, 2013, Pages 252-259

  De Castro, D Gonzalez ^a   Clarke, P A ^a   Al Lazikani, B ^a   Workman, P ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; BIOLOGICAL MARKER; CRIZOTINIB; ERLOTINIB; GEFITINIB; IMATINIB; SUNITINIB; TRASTUZUMAB; VEMURAFENIB;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CHRONIC MYELOID LEUKEMIA; CLONAL EVOLUTION; COLORECTAL CANCER; DIMERIZATION; DRUG STRUCTURE; EPITHELIAL MESENCHYMAL TRANSITION; FEEDBACK SYSTEM; GASTROINTESTINAL STROMAL TUMOR; GENOTYPE; HAIRY CELL LEUKEMIA; HUMAN; IMMUNOPHENOTYPING; LUNG NON SMALL CELL CANCER; MELANOMA; MOLECULAR DIAGNOSTICS; MOLECULAR PATHOLOGY; PERSONALIZED MEDICINE; PRIORITY JOURNAL;

DRUG RESISTANCE, NEOPLASM; HUMANS; INDIVIDUALIZED MEDICINE; MEDICAL ONCOLOGY; NEOPLASMS; PATHOLOGY, MOLECULAR; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; TUMOR MARKERS, BIOLOGICAL;

EID: 84874144193     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2012.237     Document Type: Article

References (59)

1. Collins, I. & Workman, P. New approaches to molecular cancer therapeutics. Nat. Chem. Biol. 2, 689-700 (2006
2. Yap, T.A., Sandhu, S.K., Workman, P. & de Bono, J.S. Envisioning the future of early anticancer drug development. Nat. Rev. Cancer 10, 514-523 (2010
3. Zhang, J., Yang, P.L. & Gray, N.S. Targeting cancer with small molecule kinase inhibitors. Nat. Rev. Cancer 9, 28-39 (2009
4. Giamas, G. et al. Kinases as targets in the treatment of solid tumors. Cell. Signal. 22, 984-1002 (2010
5. Gaulton, A. et al. ChEMBL: A large-scale bioactivity database for drug discovery. Nucleic Acids Res. 40, D1100-D1107 (2012
6. Halling-Brown, M.D., Bulusu, K.C., Patel, M., Tym, J.E. & Al-Lazikani, B. canSAR: An integrated cancer public translational research and drug discovery resource. Nucleic Acids Res. 40, D947-D956 (2012
7. Patel M., Halling-Brown, M.D., Tym, J.E., Workman, P. & Al-Lazikani, B. Objective assessment of cancer genes for drug discovery. Nat. Rev. Drug. Discov. 12, 35-50 (2012
8. Futreal, P.A. et al. A census of human cancer genes. Nat. Rev. Cancer 4, 177-183 (2004
9. Knapp, S.B.J., et al. A public-private partnership to unlock the untargeted kinome. Nat. Chem. Biol. 9, 3-6 (2013
10. Edwards, A.M., Isserlin, R., Bader, G.D., Frye, S.V., Willson, T.M. & Yu, F.H. Too many roads not taken. Nature 470, 163-165 (2011
11. Hoelder, S., Clarke, P.A. & Workman, P. Discovery of small molecule cancer drugs: Successes, challenges and opportunities. Mol. Oncol. 6, 155-176 (2012
12. Peeters, M. et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J. Clin. Oncol. 28, 4706-4713 (2010
13. Van Cutsem, E. et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: Updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J. Clin. Oncol. 29, 2011-2019 (2011
14. Fukuoka, M. et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced nonsmall- cell lung cancer in Asia (IPASS). J. Clin. Oncol. 29, 2866-2874 (2011
15. Mok, T.S. et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361, 947-957 (2009
16. Rosell, R. et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 13, 239-246 (2012
17. Chapman, P.B. et al.; BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507-2516 (2011
18. Hauschild, A. et al. Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial. Lancet 380, 358-365 (2012
19. Vardiman, J.W. et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114, 937-951 (2009
20. Thway, K. et al. Utility of sarcoma-specific fusion gene analysis in paraffinembedded material for routine diagnosis at a specialist centre. J. Clin. Pathol. 63, 508-512 (2010
21. Gonzalez, D. et al. Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial. J. Clin. Oncol. 29, 2223-2229 (2011
22. Pospisilova, S. et al. ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia. Leukemia 26, 1458-1461 (2012
23. Oscier, D. et al. Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation. Haematologica 95, 1705-1712 (2010
24. Gonzalez, D. et al. CLLU1 expression has prognostic value in CLL after first-line therapy in younger patients and those with mutated IGHV genes. Haematologica, (2012); e-pub ahead of print 16 August 2012
25. Paik, S. et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351, 2817-2826 (2004
26. Glas, A.M. et al. Converting a breast cancer microarray signature into a highthroughput diagnostic test. BMC Genomics 7, 278 (2006
27. B artlett, J.M. et al. Mammostrat as an Immunohistochemical Multigene Assay for Prediction of Early Relapse Risk in the Tamoxifen Versus Exemestane Adjuvant Multicenter Trial Pathology Study. J. Clin. Oncol. (2012); e-pub ahead of print 8 October 2012
28. Cuzick, J. et al. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. J. Clin. Oncol. 29, 4273-4278 (2011
29. Kantarjian, H.M. et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood 119, 1123-1129 (2012
30. Kantarjian, H.M. et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosomepositive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol. 12, 841-851 (2011
31. Schrappe, M. et al. Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. Blood 118, 2077-2084 (2011
32. Conter, V. et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood 115, 3206-3214 (2010
33. Mattocks, C.J. et al.; EuroGentest Validation Group. A standardized framework for the validation and verification of clinical molecular genetic tests. Eur. J. Hum. Genet. 18, 1276-1288 (2010
34. Kimura, T. et al. Clinical benefit of high-sensitivity KRAS mutation testing in metastatic colorectal cancer treated with anti-EGFR antibody therapy. Oncology 82, 298-304 (2012
35. Su, K.Y. et al. Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. J. Clin. Oncol. 30, 433-440 (2012
36. Gerlinger, M. et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366, 883-892 (2012
37. A nderson, K. et al. Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature 469, 356-361 (2011
38. Colombino, M. et al. BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J. Clin. Oncol. 30, 2522-2529 (2012
39. Perkins, G. et al. Multi-purpose utility of circulating plasma DNA testing in patients with advanced cancers. PLoS ONE 7, e47020 (2012
40. Tejpar, S., Celik, I., Schlichting, M., Sartorius, U., Bokemeyer, C. & Van Cutsem, E. Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. J. Clin. Oncol. 30, 3570-3577 (2012
41. B lanke C.D. et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J. Clin. Oncol. 26, 620-625 (2008
42. Verweij, J. et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 364, 1127-1134 (2004
43. Kim, E.S. et al. The BATTLE trial: Personalizing therapy for lung cancer. Cancer Discov. 1, 44-53 (2011
44. Dietrich, S., Glimm, H., Andrulis, M., von Kalle, C., Ho, A.D. & Zenz, T. BRAF inhibition in refractory hairy-cell leukemia. N. Engl. J. Med. 366, 2038-2040 (2012
45. Prahallad, A. et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 483, 100-103 (2012
46. A l-Lazikani, B., Banerji, U. & Workman, P. Combinatorial drug therapy for cancer in the post-genomic era. Nat. Biotechnol. 30, 679-692 (2012
47. Garraway L.A. & Janne P.A. Circumventing cancer drug resistance in the era of personalized medicine. Cancer Discov. 2, 214-226 (2012
48. Workman, P. & Clarke, P.A. Resisting targeted therapy: fifty ways to leave your EGFR. Cancer Cell. 19, 437-440 (2011
49. Postel-Vinay, S. & Ashworth, A. AXL and acquired resistance to EGFR inhibitors. Nat. Genet. 44, 835-836 (2012
50. B ivona, T.G. et al. FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR. Nature 471, 523-526 (2011
51. Sequist, L.V. et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci. Transl. Med. 3, 75ra26 (2011
52. Rekhtman, N. et al. Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: Lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations. Clin. Cancer Res. 18, 1167-1176 (2012
53. Voulgari, A. & Pintzas, A. Epithelial-mesenchymal transition in cancer metastasis: Mechanisms, markers and strategies to overcome drug resistance in the clinic. Biochim. Biophys. Acta 1796, 75-90 (2009
54. Nurwidya, F., Takahashi, F., Murakami, A. & Takahashi, K. Epithelial mesenchymal transition in drug resistance and metastasis of lung cancer. Cancer Res. Treat. 44, 151-156 (2012
55. Huang, S. et al. MED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signaling. Cell 151, 937-950 (2012
56. Miller, V.A. et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): A phase 2b/3 randomised trial. Lancet Oncol. 13, 528-538 (2012
57. Chmielecki, J. et al. Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci. Transl. Med. 3, 90ra59 (2011
58. Yap, T.A. & Workman, P. Exploiting the cancer genome: Strategies for the discovery and clinical development of targeted molecular therapeutics. Annu. Rev. Pharmacol. Toxicol. 52, 549-573 (2012
59. Chen, R. et al. Personal omics profiling reveals dynamic molecular and medical phenotypes. Cell 148, 1293-1307 (2012